A clinical trial for a new personalized cancer vaccine called TG4050 has reached a key step. The study, which is testing the vaccine for head and neck cancer patients after surgery and chemotherapy, has now randomly assigned all 38 patients in the second part of the trial. Researchers expect to share the first results on whether the vaccine helps prevent cancer from returning by the end of the first three months of 2028. The vaccine is created using a special platform called myvac, which helps the body’s immune system target cancer cells more effectively to stop the disease from coming back.